186.50 -0.17 (-0.09%)
After hours: 6:12PM EST
|Bid||185.60 x 1000|
|Ask||187.55 x 200|
|Day's range||182.77 - 186.79|
|52-week range||152.16 - 201.23|
|PE ratio (TTM)||69.39|
|Earnings date||24 Apr 2018 - 30 Apr 2018|
|Forward dividend & yield||5.28 (2.89%)|
|1y target est||195.67|
Novartis: What Are the Major Growth Drivers for 2018? On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the patients with ankylosing spondylitis. According to the Arthritis Foundation, “Spondyloarthritis is an umbrella term for inflammatory diseases that involve both the joints and the entheses (the sites where the ligaments and tendons attach to the bones).
Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.
Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.
Novartis: What Are the Major Growth Drivers for 2018? In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year (or YoY) increase of 53.0% on a constant currency basis and 11.0% growth quarter-over-quarter. This growth was driven by the drug’s rapid uptake in all approved indications and in all geographies, with a focus on the US and Europe.
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
The future of the expensive new cholesterol drugs largely depends on the results of the Sanofi/Regeneron ODYSSEY Outcomes trial coming out next month.
After 4Q17, Amgen (AMGN) anticipates its net revenues for 2018 to be $21.8 billion–$22.8 billion. It expects non-GAAP (generally accepted accounting principles) to be $12.60–$13.70 and its tax rate to be 14%–15%. Amgen estimated capital expenditure for 2018 of $750 million.
For 4Q17, Novartis’s (NVS) Entresto reported sales of $185 million around the world, which represents a YoY (year-over-year) rise of 172% on a reported basis and a 164% YoY rise on a CC (constant currency) basis. Novartis reported Entresto sales of ~$507 million for fiscal 2017, which represents a YoY rise of ~198% on a reported basis. Novartis has now launched Entresto in almost 60 countries worldwide, with its latest launch just completed in China.
In January 2018, the European Commission (or EC) approved Amgen’s (AMGN) and Allergan’s (AGN) Marketing Authorization Application (or MAA) for Mvasi, a biosimilar to Roche’s (RHHBY) Avastin (bevacizumab). Amgen’s Mvasi became the first bevacizumab biosimilar to be approved by the EC for the treatment of particular types of cancer. In January 2018, Amgen presented positive results from its Phase 3b LIBERTY trial.
In 4Q17, Amgen’s (AMGN) Aranesp generated revenues of $491 million, which reflected a 7% decline on a YoY (year-over-year) basis and a 5% decline quarter-over-quarter. In 4Q17 in the US and international markets, Aranesp generated revenues of $263 million and $228 million, respectively. Lower unit demand and unfavorable changes in foreign exchange rates primarily led to the decline in revenues in 4Q17.